Cancer treatment and research communications最新文献

{"title":"Unveiling the genetic landscape of hereditary melanoma: From susceptibility to surveillance","authors":"","doi":"10.1016/j.ctarc.2024.100837","DOIUrl":"10.1016/j.ctarc.2024.100837","url":null,"abstract":"<div><p>The multifactorial etiology underlying melanoma development involves an array of genetic, phenotypic, and environmental factors. Genetic predisposition for melanoma is further influenced by the complex interplay between high-, medium-, and low-penetrance genes, each contributing to varying degrees of susceptibility. Within this network, high-penetrance genes, including <em>CDKN2A, CDK4, BAP1</em>, and <em>POT1,</em> are linked to a pronounced risk for disease, whereas medium- and low-penetrance genes, such as <em>MC1R, MITF</em>, and others, contribute only moderately to melanoma risk. Notably, these genetic factors not only heighten the risk of melanoma but may also increase susceptibility towards internal malignancies, such as pancreatic cancer, renal cell cancer, or neural tumors. Genetic testing and counseling hold paramount importance in the clinical context of suspected hereditary melanoma, facilitating risk assessment, personalized surveillance strategies, and informed decision-making. As our understanding of the genomic landscape deepens, this review paper aims to comprehensively summarize the genetic underpinnings of hereditary melanoma, as well as current screening and management strategies for the disease.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000492/pdfft?md5=9f10c8ce18e2ed33ecd14aa1c68588fa&pid=1-s2.0-S2468294224000492-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rectal cancer survival and prognostic factors in Iranian population: A retrospective cohort study","authors":"Seyed Kazem Mirinezhad ,&nbsp;Mostafa Akbarzadeh-Khiavi ,&nbsp;Farshad Seyednejad ,&nbsp;Mohammad Hossein Somi","doi":"10.1016/j.ctarc.2024.100810","DOIUrl":"10.1016/j.ctarc.2024.100810","url":null,"abstract":"<div><h3>Background</h3><p>Rectal cancer (RC) poses a significant global health challenge, causing substantial morbidity and mortality. This study aims to investigate the survival rates of RC patients and identify the factors that influence their survival. The study considers demographic characteristics, tumor features, and treatment received as the factors under consideration.</p></div><div><h3>Methods</h3><p>A retrospective analysis was conducted on the medical records of 593 RC patients. Data were collected through a comprehensive review of medical records and conducting telephone interviews. Survival rates were estimated using the life table method, and subgroup comparisons were performed using the log-rank test. Cox regression analysis was utilized to assess the independent associations between RC survival time and various covariates.</p></div><div><h3>Results</h3><p>The study cohort comprised 593 RC patients, with a predominantly male representation. The mean age at diagnosis was 58.18 years, and the majority of patients (78.6 %) underwent surgical interventions. The median age at symptom onset and diagnosis were 58 and 59 years, respectively. Survival rates at 1st, 3rd, 5th, and 10th years were estimated to be 85 %, 59 %, 47 %, and 36 %, respectively. Statistical analysis revealed several significant prognostic factors, including age, education, symptoms, and cancer stage. In the multivariate Cox proportional-hazards analysis, advanced regional stage (HR = 1.54, 95 % CI, 1.13–2.08), presence of metastasis (HR = 3.73, 95 % CI, 2.49–5.58), and age over 70 (HR = 1.65) were associated with a higher risk of mortality.</p></div><div><h3>Conclusion</h3><p>Given the alarming prognosis of RC observed in the study area and the significant delay between symptom onset and diagnosis, it is crucial to address this issue and potentially improve the survival rates of RC patients.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000224/pdfft?md5=f3cd7f224a762464d244f0a233e484b3&pid=1-s2.0-S2468294224000224-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140402897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes of physicians and patients toward immediate and intraoperative chemotherapy treatment in colon cancer","authors":"Mehraneh D. Jafari ,&nbsp;Andrea Mesiti ,&nbsp;Julianna Brouwer ,&nbsp;Chelsea McKinney ,&nbsp;Lari B. Wenzel ,&nbsp;Alessio Pigazzi ,&nbsp;Jason A. Zell","doi":"10.1016/j.ctarc.2024.100798","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100798","url":null,"abstract":"<div><h3>Introduction</h3><p>We have shown in a Phase I trial that immediate adjuvant chemotherapy (IAC) during surgical resection and immediately postoperative is safe and feasible in patients with colon cancer (CC). IAC avoids delays in adjuvant treatment and has the potential to improve survival and quality of life. We aim to determine patients and providers attitudes toward this novel multidisciplinary treatment approach.</p></div><div><h3>Methods</h3><p>Two web-based surveys were administered to newly diagnosed CC patients, survivors, surgeons and oncologists. Surveys assessed treatment preferences and perceived barriers to IAC. Chi-square tests were conducted to compare differences between patients’ and providers’ responses.</p></div><div><h3>Results</h3><p>Responses were collected from 35 patients and 40 providers. Patients were more willing to: (1) proceed with IAC to finish treatment earlier thus possibly improving quality of life (<em>p</em> = 0.001); (2) proceed with IAC despite potential side effects (<em>p</em> &lt; 0.001); and (3) proceed with a dose of intraoperative chemotherapy even if on final pathology, may not have been needed (<em>p</em> = 0.002). Patients were more likely to indicate no barriers to collaborative care (<em>p</em> = 0.001) while providers were more likely to cite that it is time consuming, thus a barrier to participation (<em>p</em> = 0.001), has scheduling challenges (<em>p</em> = 0.001), and physicians are not available to participate (<em>p</em> = 0.003).</p></div><div><h3>Conclusions</h3><p>We observed a discordance between what providers and patients value in perioperative and adjuvant CC treatment. Patients are willing to accept IAC despite potential side effects and without survival benefit, highlighting the importance of understanding patient preference.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000108/pdfft?md5=8ca70afb2272b954ac368cf708081f3c&pid=1-s2.0-S2468294224000108-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140030977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy","authors":"Sajjad Ahmadpour ,&nbsp;Mohammad Amin Habibi ,&nbsp;Farzaneh Sadat Ghazi ,&nbsp;Mikaeil Molazadeh ,&nbsp;Mohammad Reza Pashaie ,&nbsp;Yousef Mohammadpour","doi":"10.1016/j.ctarc.2024.100823","DOIUrl":"10.1016/j.ctarc.2024.100823","url":null,"abstract":"<div><p>Tumors can produce bioactive substances called tumor-derived supernatants (TDS) that modify the immune response in the host body. This can result in immunosuppressive effects that promote the growth and spread of cancer. During tumorigenesis, the exudation of these substances can disrupt the function of immune sentinels in the host and reinforce the support for cancer cell growth. Tumor cells produce cytokines, growth factors, and proteins, which contribute to the progression of the tumor and the formation of premetastatic niches. By understanding how cancer cells influence the host immune system through the secretion of these factors, we can gain new insights into cancer diagnosis and therapy.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000352/pdfft?md5=50a6996ac4bc66271d4187b169d09594&pid=1-s2.0-S2468294224000352-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141278925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment","authors":"","doi":"10.1016/j.ctarc.2024.100836","DOIUrl":"10.1016/j.ctarc.2024.100836","url":null,"abstract":"<div><h3>Background</h3><p>The most recommended treatment for stage IV EGFR-positive lung cancer is osimertinib monotherapy. The dosage of osimertinib is fixed at 80 mg/day regardless of body surface area (BSA), however some patients withdraw or reduce the dosage due to adverse events (AEs).</p></div><div><h3>Methods</h3><p>We performed a retrospective cohort study of 98 patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who received 80 mg osimertinib as the initial treatment. We investigated the impact of BSA on efficacy and safety of osimertinib.</p></div><div><h3>Results</h3><p>The cut-off value of BSA was estimated using the receiver operating characteristics curve, and was determined to be 1.5 m². There were 44 patients in the BSA &lt; 1.5 group and 54 patients in the BSA ≥ 1.5 group. There was no significant difference in the incidence of AEs (hematologic toxicity of ≥grade 3 or higher, and non-hematologic toxicity of ≥grade 3) between the two groups. However, the incidence of dose reduction due to AEs was significantly higher in the BSA &lt; 1.5 group compared with the BSA ≥ 1.5 group (16 patients vs 5 patients, <em>p</em> = 0.003). The main reasons were fatigue, anorexia, diarrhea, and liver disfunction. Median progression-free survival (PFS) was not significantly different (16.9 months in the BSA &lt; 1.5 group vs 18.1 months in the BSA ≥ 1.5 group, <em>p</em> = 0.869).</p></div><div><h3>Conclusion</h3><p>Differences in BSA affected the optimal dose of osimertinib. However, the PFS with osimertinib treatment was not affected by BSA. Therefore, when using osimertinib as an initial treatment for patients with EGFR-mutant NSCLC, dose reduction to control AEs should be considered, especially in the BSA&lt;1.5 group.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000480/pdfft?md5=9618c1dc15ff3738502bc6dd4ff016f7&pid=1-s2.0-S2468294224000480-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of villin expression and tumor behavior in colorectal cancer","authors":"Seyed Amir Miratashi Yazdi ,&nbsp;Elahe Farmani ,&nbsp;Sara Shahvaisi ,&nbsp;Arezoo Eftekhar Javadi ,&nbsp;Elham Nazar","doi":"10.1016/j.ctarc.2024.100825","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100825","url":null,"abstract":"<div><h3>Background</h3><p>Colorectal cancer is one of the most common cancers and the leading cause of cancer-related deaths worldwide. The incidence is gradually increasing, and the mortality and recurrence rates of the disease remain high.</p></div><div><h3>Methods</h3><p>This study was conducted as a cross-sectional study using tissue samples of 106 patients who underwent surgery at Sina Hospital from 2021 to 2022. After histopathological examination and identification of the pathological features of the tumor, the samples were subjected to immunohistochemical staining using a monoclonal antibody against villin.</p></div><div><h3>Results</h3><p>In this study, we observed a significant association between villin expression and tumor depth, as well as a correlation between villin expression and tumor location (colon or rectum). However, no association was found between villin expression and the number of affected lymph nodes and age, sex, tumor grade, and size. Furthermore, there was no significant association between villin expression and tumor vascular or neural invasion.</p></div><div><h3>Conclusion</h3><p>The extent of local invasion and metastasis are important factors in disease progression and can lead to treatment failure. Therefore, new biomarkers are needed to identify patients at risk of local and distant metastases and to enable appropriate treatment of patients.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000376/pdfft?md5=563e8cb56d3b808fb46552b342b8cb72&pid=1-s2.0-S2468294224000376-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141291479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion–mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study","authors":"","doi":"10.1016/j.ctarc.2024.100832","DOIUrl":"10.1016/j.ctarc.2024.100832","url":null,"abstract":"<div><h3>Background</h3><p>Amivantamab, an EGFR-MET bispecific antibody, is the first approved targeted therapy for patients with <em>EGFR</em> Ex20ins NSCLC after prior platinum-based chemotherapy—a population with historically poor outcomes before amivantamab approval. As antitumor activity in single-arm studies typically focuses on responders, the evaluation of outcomes in patients with stable disease (SD) as best response is of clinical interest.</p></div><div><h3>Patients and methods</h3><p>Among 114 patients with post-platinum <em>EGFR</em> Ex20ins NSCLC in CHRYSALIS (NCT02609776; data cutoff: March 30, 2021), response was assessed by blinded independent central review via RECIST v1.1. Patients alive and receiving therapy at 12 weeks were grouped by response at this landmark: partial or complete response (PR+), SD, or progressive disease (PD). Progression-free survival (PFS) and overall survival (OS) by response cohort were determined using the Kaplan-Meier method; hazard ratios (HRs) and 95% confidence intervals (CIs) between response cohorts were calculated using Cox proportional hazards regression.</p></div><div><h3>Results</h3><p>Among patients alive and receiving therapy at 12 weeks (n=107), 42 (39%) had PR+, 52 (49%) had SD, and 13 (12%) had PD. Among patients with PR+ and SD, median PFS was 12.2 and 7.0 months, respectively. A corresponding improvement in OS was observed in patients achieving PR+ (median: not reached; HR vs PD=0.21 [95% CI: 0.08–0.54]) and SD (median: 23.0 months; HR vs PD=0.33 [95% CI: 0.14–0.77]), relative to those with PD (median: 14.0 months).</p></div><div><h3>Conclusion</h3><p>SD was observed in 49% of patients receiving amivantamab, with corresponding increases in OS that dramatically improved the prognoses of this patient population.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000443/pdfft?md5=5f37518a464c8ffe36c0b6772e0ef5c3&pid=1-s2.0-S2468294224000443-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141703919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive structural and functional analysis of hVEGFR1: Insights into phosphorylation, molecular interactions, and potential inhibitors through docking and dynamics simulations","authors":"Manne Munikumar ,&nbsp;Jangampalli Adi Pradeepkiran ,&nbsp;Marineni Kiran Kumar ,&nbsp;Swathi Banapuram ,&nbsp;Akshatha Bhat Edurkala","doi":"10.1016/j.ctarc.2024.100795","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100795","url":null,"abstract":"<div><p>Vascular Endothelial Growth Factor Receptor 1 (VEGFR1), is an enzyme with tyrosine kinase activity that plays a pivotal role in angiogenesis, the process of new blood vessel formation. This receptor is of significant clinical importance as it is implicated in various cancers, particularly non-small cell lung cancer (NSCLC), where its dysregulation leads to uncontrolled cell growth through ligand-induced phosphorylation. While commercially available drugs target VEGFR1, their prolonged use often leads to drug resistance and the emergence of mutations in cancer patients. To address these challenges, researchers have identified the human tyrosine kinase (hTK) domain of VEGFR1 as a potential therapeutic marker for lung malignancies. The 3D crystal structure of the hTK domain, obtained from Protein Data Bank (PDB ID: 3HNG), has provided vital structural insights of hVEGFR1. This study has revealed variations within the hVEGFR1 tyrosine kinase domain, distinguishing between regions associated with phosphorylase kinase and transferase activities. We identified numerous potential phosphorylation sites within the TK domain, shedding light on the protein's regulation and signaling possible. Detailed molecular interaction analyses have elucidated the binding forces between lead molecules and hVEGFR1, including hydrogen bonds, electrostatic, hydrophobic, and π-sigma interactions. The stability observed during molecular dynamics simulations further underscores the biological relevance of these interactions. Furthermore, docked complexes has highlighted localized structural fluctuations, offering insight into potential allosteric effects and dynamic conformational changes induced by lead molecules. These findings not only provide a comprehensive characterization of hVEGFR1 but also pave the way for the development of targeted therapies. Eventually, this study has the potential in identifying drug to combat diseases associated with hVEGFR1 dysregulation, including cancer and angiogenesis-related disorders, contributing to effective treatment strategies.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000078/pdfft?md5=fa69e823274f13764b97a36afc9dc2d3&pid=1-s2.0-S2468294224000078-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139993248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming the landscape of colorectal cancer treatment with immunotherapy: Evolution and future horizons","authors":"Jan Clerick,&nbsp;Aude Van Oosterwyck,&nbsp;Saskia Carton","doi":"10.1016/j.ctarc.2024.100807","DOIUrl":"10.1016/j.ctarc.2024.100807","url":null,"abstract":"<div><p>Colorectal cancer (CRC) continues to be one of the most prevalent and lethal cancers worldwide. Over the past decades, immune checkpoint inhibitors (ICIs) have shown to significantly improve patient outcomes in mismatch repair-deficient metastasized CRC. However, widening the scope of this novel treatment modality has been the object of growing interest. This article will review several landmark trials, while exploring various aspects of this rapidly evolving field, including potential neoadjuvant (or even entirely nonsurgical) and adjuvant indications in localized disease. We will also discuss differences between management of rectal and colon cancer, current and expected challenges (eg. resistance, toxicities, pseudoprogression, biomarkers) and other future opportunities including combinations with other therapeutic agents and the role of ICIs in the treatment of both deficient as well as proficient mismatch repair (dMMR and pMMR respectively) CRC.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000194/pdfft?md5=ce28e34b1a8382f122e7522d2118a6a4&pid=1-s2.0-S2468294224000194-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140093444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptomes of cervical cancer provide novel insights into dysregulated pathways, potential therapeutic targets, and repurposed drugs","authors":"Md Tamzid Hossain Tanim ,&nbsp;Sudipta Deb Nath ,&nbsp;Sumaiya Farah Khan ,&nbsp;Abira Khan ,&nbsp;Abu Ashfaqur Sajib","doi":"10.1016/j.ctarc.2024.100808","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100808","url":null,"abstract":"<div><p>Cervical cancer ranks as the fourth most prevalent gynaecological malignancy and is a significant contributor to mortality among women globally. With the exception of HPV-mediated oncogenesis, the molecular etiology of the disease is poorly understood, and there is a critical dearth of knowledge concerning cancer that is not caused by HPV. Moreover, none of the options presently accessible for the treatment of cancers specifically target cervical cancer. In context with this, this research aims to identify the critical genes, regulators, and pathways that contribute to the pathogenesis of cervical cancer, in addition to prospective pharmacological targets and repurposed therapeutic agents that can be directed against the targets. A total of eleven different global gene expression (transcriptome) datasets were subjected to analysis utilizing a variety of <em>in silico</em> tools. The present study reveals a previously unknown correlation between cervical cancer and five genes: SHC1, CBL, GNAQ, GNA14, and PPP2CA. Significant dysregulation was observed in four crucial transcription factors (KLF4, E2F1, FOXM1, and AR) that modulate the expression of numerous genes in cervical cancer. Furthermore, it was observed that AKT1, MAPK1, and MAPK3 ranked the highest among the regulatory genes that hold promise as therapeutic targets in the context of cervical cancer. Additional research, both <em>in vitro</em> and <em>in vivo</em>, is required to validate and establish the therapeutic potential of these crucial genes in the context of cervical cancer.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000200/pdfft?md5=3105e45c411aa9f76d95dbd7dc4e1856&pid=1-s2.0-S2468294224000200-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140296898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}